Prothena Q1 net loss $72.2M ($1.34/sh); cash $548.7M; guides FY 2024 cash burn $208-225M

PROTHENA CORP PUBLIC LTD CO

2024-Q1 EPS reported -$1.34 revenue$50,000

Net loss $72.2M vs $46.9M YoY; revenue $0.1M vs $2.2M; R&D expenses $64.1M vs $44.8M.
Cash, equivalents & restricted cash $548.7M (no debt); expects ~$405M year-end 2024.
Phase 3 AFFIRM-AL (birtamimab) topline data expected 4Q24–2Q25; Phase 1 PRX012 update in 2024.
Bristol Myers Squibb initiated Phase 2 for BMS-986446 (tau antibody) in early Alzheimer’s.
Daniel G. Welch appointed independent director and Chair Designate; David Ford named Chief People Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

PROTHENA CORP PUBLIC LTD CO reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Prothena Corporation plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

PROTHENA CORP PUBLIC LTD CO filing history →

Source: SEC EDGAR

accession 0001559053-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.